Literature DB >> 20167853

The role of surfactant protein A in bleomycin-induced acute lung injury.

Hisatsugu Goto1, Julie G Ledford, Sambuddho Mukherjee, Paul W Noble, Kristi L Williams, Jo Rae Wright.   

Abstract

RATIONALE: Surfactant protein A (SP-A) is a collectin family member that has multiple immunomodulatory roles in lung host defense. SP-A levels are altered in the bronchoalveolar lavage (BAL) fluid and serum of patients with acute lung injury and acute respiratory distress syndrome, suggesting the importance of SP-A in the pathogenesis of acute lung injury.
OBJECTIVES: Investigate the role of SP-A in the murine model of noninfectious lung injury induced by bleomycin treatment.
METHODS: Wild-type (WT) or SP-A deficient (SP-A(-/-)) mice were challenged with bleomycin, and various indices of lung injury were analyzed.
MEASUREMENTS AND MAIN RESULTS: On challenge with bleomycin, SP-A(-/-) mice had a decreased survival rate as compared with WT mice. SP-A(-/-) mice had a higher degree of neutrophil-dominant cell recruitment and the expression of the inflammatory cytokines in BAL fluid than did WT mice. In addition, SP-A(-/-) mice had increased lung edema as assessed by the increased levels of intravenously injected Evans blue dye leaking into the lungs. Terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick end labeling and active caspase-3 staining suggested the increased apoptosis in the lung sections from SP-A(-/-) mice challenged with bleomycin. SP-A also specifically reduced bleomycin-induced apoptosis in mouse lung epithelial 12 cells in vitro. Moreover, intratracheal administration of exogenous SP-A rescued the phenotype of SP-A(-/-) mice in vivo.
CONCLUSIONS: These data suggest that SP-A plays important roles in modulating inflammation, apoptosis, and epithelial integrity in the lung in response to acute noninfectious challenges.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20167853      PMCID: PMC2894409          DOI: 10.1164/rccm.200907-1002OC

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  43 in total

1.  CD44 is a negative regulator of acute pulmonary inflammation and lipopolysaccharide-TLR signaling in mouse macrophages.

Authors:  Jiurong Liang; Dianhua Jiang; Jason Griffith; Shuang Yu; Juan Fan; Xiaojian Zhao; Richard Bucala; Paul W Noble
Journal:  J Immunol       Date:  2007-02-15       Impact factor: 5.422

2.  Surfactant-associated protein A inhibits LPS-induced cytokine and nitric oxide production in vivo.

Authors:  P Borron; J C McIntosh; T R Korfhagen; J A Whitsett; J Taylor; J R Wright
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2000-04       Impact factor: 5.464

3.  Serial changes in surfactant-associated proteins in lung and serum before and after onset of ARDS.

Authors:  K E Greene; J R Wright; K P Steinberg; J T Ruzinski; E Caldwell; W B Wong; W Hull; J A Whitsett; T Akino; Y Kuroki; H Nagae; L D Hudson; T R Martin
Journal:  Am J Respir Crit Care Med       Date:  1999-12       Impact factor: 21.405

4.  HMG-1 as a mediator of acute lung inflammation.

Authors:  E Abraham; J Arcaroli; A Carmody; H Wang; K J Tracey
Journal:  J Immunol       Date:  2000-09-15       Impact factor: 5.422

5.  Evidence of type II pneumocyte apoptosis in the pathogenesis of idiopathic pulmonary fibrosis (IFP)/usual interstitial pneumonia (UIP).

Authors:  J V Barbas-Filho; M A Ferreira; A Sesso; R A Kairalla; C R Carvalho; V L Capelozzi
Journal:  J Clin Pathol       Date:  2001-02       Impact factor: 3.411

6.  Cyclooxygenase-2 deficiency exacerbates bleomycin-induced lung dysfunction but not fibrosis.

Authors:  Jeffrey W Card; James W Voltz; Michelle A Carey; J Alyce Bradbury; Laura M Degraff; Fred B Lih; James C Bonner; Daniel L Morgan; Gordon P Flake; Darryl C Zeldin
Journal:  Am J Respir Cell Mol Biol       Date:  2007-05-11       Impact factor: 6.914

Review 7.  Acute lung injury and the acute respiratory distress syndrome: a clinical review.

Authors:  Arthur P Wheeler; Gordon R Bernard
Journal:  Lancet       Date:  2007-05-05       Impact factor: 79.321

8.  A Search for subgroups of patients with ARDS who may benefit from surfactant replacement therapy: a pooled analysis of five studies with recombinant surfactant protein-C surfactant (Venticute).

Authors:  Friedemann J H Taut; Gerd Rippin; Peter Schenk; George Findlay; Wilhelm Wurst; Dietrich Häfner; James F Lewis; Werner Seeger; Andreas Günther; Roger G Spragg
Journal:  Chest       Date:  2008-08-08       Impact factor: 9.410

9.  Pulmonary surfactant protein A regulates TLR expression and activity in human macrophages.

Authors:  Lisa N Henning; Abul K Azad; Kishore V L Parsa; Joy E Crowther; Susheela Tridandapani; Larry S Schlesinger
Journal:  J Immunol       Date:  2008-06-15       Impact factor: 5.422

Review 10.  Animal models of acute lung injury.

Authors:  Gustavo Matute-Bello; Charles W Frevert; Thomas R Martin
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2008-07-11       Impact factor: 5.464

View more
  33 in total

Review 1.  Toll like receptors in diseases of the lung.

Authors:  Melissa A Kovach; Theodore J Standiford
Journal:  Int Immunopharmacol       Date:  2011-05-30       Impact factor: 4.932

Review 2.  Update in acute lung injury and critical care 2010.

Authors:  István Vadász; Jacob I Sznajder
Journal:  Am J Respir Crit Care Med       Date:  2011-05-01       Impact factor: 21.405

3.  Role of surfactant proteins A and D in sepsis-induced acute kidney injury.

Authors:  Jiao Liu; Osama Abdel-Razek; Zhiyong Liu; Fengqi Hu; Qingshan Zhou; Robert N Cooney; Guirong Wang
Journal:  Shock       Date:  2015-01       Impact factor: 3.454

4.  Hyperoxia treatment of TREK-1/TREK-2/TRAAK-deficient mice is associated with a reduction in surfactant proteins.

Authors:  Andreas Schwingshackl; Benjamin Lopez; Bin Teng; Charlean Luellen; Florian Lesage; John Belperio; Riccardo Olcese; Christopher M Waters
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2017-08-24       Impact factor: 5.464

5.  Genetic Variation in Surfactant Protein-A2 Delays Resolution of Eosinophilia in Asthma.

Authors:  Alane Blythe C Dy; Muhammad Z Arif; Kenneth J Addison; Loretta G Que; Scott Boitano; Monica Kraft; Julie G Ledford
Journal:  J Immunol       Date:  2019-07-26       Impact factor: 5.422

6.  Surfactant protein A suppresses lung cancer progression by regulating the polarization of tumor-associated macrophages.

Authors:  Atsushi Mitsuhashi; Hisatsugu Goto; Takuya Kuramoto; Sho Tabata; Sawaka Yukishige; Shinji Abe; Masaki Hanibuchi; Soji Kakiuchi; Atsuro Saijo; Yoshinori Aono; Hisanori Uehara; Seiji Yano; Julie G Ledford; Saburo Sone; Yasuhiko Nishioka
Journal:  Am J Pathol       Date:  2013-03-14       Impact factor: 4.307

Review 7.  Animal models of fibrotic lung disease.

Authors:  Bethany B Moore; William E Lawson; Tim D Oury; Thomas H Sisson; Krishnan Raghavendran; Cory M Hogaboam
Journal:  Am J Respir Cell Mol Biol       Date:  2013-08       Impact factor: 6.914

Review 8.  Eosinophil-associated lung diseases. A cry for surfactant proteins A and D help?

Authors:  Julie G Ledford; Kenneth J Addison; Matthew W Foster; Loretta G Que
Journal:  Am J Respir Cell Mol Biol       Date:  2014-11       Impact factor: 6.914

9.  Dipeptidyl peptidase IV is a human and murine neutrophil chemorepellent.

Authors:  Sarah E Herlihy; Darrell Pilling; Anu S Maharjan; Richard H Gomer
Journal:  J Immunol       Date:  2013-05-15       Impact factor: 5.422

10.  Effects of basic drugs on prognosis of acute lung injury in mice.

Authors:  Liming Jia; Junming Ren; Weiwei Zhang; Yuehong Qi; Lina Zheng; Yongqing Guo
Journal:  Int J Clin Exp Med       Date:  2015-10-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.